News

Metastatic CRC treatment ‘dynamic and fast changing’


 

EXPERT ANALYSIS FROM ICACT 2015

References

Another “new kid on the block” yet to be approved and incorporated into the guidelines is TAS-102, an oral fluoropyrimidine. Data from the recent RECOURSE study (Refractory Colorectal Cancer Study) showed an overall survival benefit of the novel drug vs. placebo when added to best supportive care after two or more prior regimens for mCRC (Ann. Oncol. 2014;25-4: Abstr. LBA13).

Dr. Van Cutsem has received research funding from Amgen, Bayer, Boehringer, Lilly, Merck, Merck Serono, Novartis, Roche, and Sanofi.

Pages

Recommended Reading

Choose colonoscopy over sigmoidoscopy for screening of proximal advanced serrated lesions
MDedge Hematology and Oncology
David Henry's JCSO podcast, January 2015
MDedge Hematology and Oncology
Older age doesn’t preclude use of ramucirumab for gastric cancers
MDedge Hematology and Oncology
New immunomodulator shows promise in pancreatic cancer
MDedge Hematology and Oncology
Jury still out on survival benefit of resecting primary in mCRC
MDedge Hematology and Oncology
Mortality low in multisite study of MIE
MDedge Hematology and Oncology
Smoking linked to many ‘new’ causes of death
MDedge Hematology and Oncology
HPV-16 E6 seropositivity common before anal cancer develops
MDedge Hematology and Oncology
Low marks for bevacizumab in cost/benefit analysis
MDedge Hematology and Oncology
Joint breast and colorectal cancer screenings in medically underserved women
MDedge Hematology and Oncology